Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.
Arms and Interventions
MGCD0103 Oral 2 times weekly
Oral dosage 2 times weekly.
Primary Outcome Measures
- Safety and tolerability [1 year (anticipated)]
Secondary Outcome Measures
- Clinical response [1 year (anticipated)]
- Pharmacokinetics [1 year (anticipated)]
- Pharmacodynamics (histone acetylation; biomarkers) [1 year (anticipated)]
- Patients must have histologically or cytologically documented advanced or metastatic solid malignancy or aggressive NHL with no reasonable likelihood of achieving clinical benefit with existing therapies, that has failed to respond to standard therapy, has progressed despite standard therapy, or for which no standard therapy exists.
Aggressive forms of NHL eligible for the study are:
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Follicle-center cell lymphoma, large cell
Primary mediastinal large B-cell lymphoma
Patients with known central nervous system (CNS) metastases may be enrolled if they have received radiotherapy for their CNS disease, if they have been on a stable dose of steroids for at least 1 month prior to study entry, if they have had computed tomography (CT) or magnetic resonance imaging (MRI) of the brain within 1 month of study entry that shows stable disease and if they are free of neurological symptoms.
Prior therapies allowed:
Hormonal therapy/other therapy
Luteinizing hormone releasing hormone (LHRH) agonist therapy
Adjuvant therapy - Patients may have had unlimited prior adjuvant therapy. A minimum of 28 days must have passed since the end of last treatment and study initiation. Patients must have recovered from any treatment-related toxicities.
ECOG performance status of 0, 1, or 2.
Age ≥ 18 years.
Minimum life expectancy of at least 3 months.
Patients with a history of another cancer other than basal cell carcinoma or cervical intraepithelial neoplasia (CIN/cervical in situ) unless the previous cancer was treated and the patient has remained disease free for five years or more prior to the current cancer diagnosis. Investigators desiring to enter patients with a second malignancy must discuss with and obtain written approval in advance from the MethylGene Medical Monitor.
Pregnant or lactating women. Women of child-bearing potential must have a negative serum pregnancy test documented within 7 days prior to registration on study.
Patients and their partners, if either are of child-bearing potential, not using adequate birth control measures throughout the course of the study. Both men and women enrolled on study must agree to use a medically acceptable effective form of contraception during the study and for 90 days following the last dose of study medication. An effective form of contraception is an oral contraceptive or a double barrier method, such as condom with diaphragm.
Patients with known meningeal metastasis(es)
Patients with active or uncontrolled infections, or with a fever > 38.5 degrees Celsius on the day of scheduled dosing
Patients with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a patient's participation in the study, or with the interpretation of the results
Patients who have been treated with any investigational drug within 30 days prior to study initiation (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Known hypersensitivity to histone deacetylase (HDAC) inhibitors or any of the components of MGCD0103
Known HIV or hepatitis B or C (active, prior treated, or both).
Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc) that, in the judgment of the investigator, may affect the patient's ability to sign the informed consent and undergo study procedures.
Contacts and Locations
|1||The Johns Hopkins Hospital||Baltimore||Maryland||United States||21205|
|2||Princess Margaret Hospital||Toronto||Ontario||Canada||M5G 2M9|
|3||Hopital Charles LeMoyne||Greenfield Park||Quebec||Canada||J4V 2H1|
Sponsors and Collaborators
- Mirati Therapeutics Inc.
- Study Director: Gregory Reid, MSc, MBA, MethylGene Inc.
Study Documents (Full-Text)None provided.